title: Is surgical debridement and topical 5 fluorouracil the optimum treatment for woodworkers' adenocarcinoma of the ethmoid sinuses? A case-controlled study of a 20-year experience.
abstract: OBJECTIVE
  Woodworkers' adenocarcinoma of the ethmoid sinuses is an extremely rare occupational malignancy with a locally aggressive course. Treatment with surgical exenteration and topical 5 fluorouracil (5FU) packs has become standard treatment over the last 10 years in this ENT unit. This study presents level 2 evidence that 5FU provides improved survival over previous management with primary radiotherapy and salvage craniofacial resection.
  
  
  METHODS
  Retrospective case series with historical control group.
  
  
  METHODS
  District General Hospital.
  
  
  METHODS
  The records of 31 consecutive patients with the disease were analysed. Five patients died prior to treatment. One patient was treated with surgery alone and therefore excluded. Twenty-five patients were included in the analysis. Fourteen were treated with primary radiotherapy and 11 with surgery and topical 5FU.
  
  
  METHODS
  Disease free survival was measured using Kaplan-Meier survival analysis.
  
  
  RESULTS
  Five-year disease free survival improved from 50% with primary radiotherapy to 86% with surgery and 5FU. This improvement is statistically significant (P = 0.03).
  
  
  CONCLUSIONS
  Topical 5FU treatment improves survival of Woodworker's adenocarcinoma of the ethmoid sinuses. This finding may be useful in the treatment of other locally aggressive sinonasal malignancies.
authors.affiliation: Department of Otolaryngology, Wexham Park Hospital, Berks, UK. robalmeyda@yahoo.co.uk
authors.forename: R
authors.initials: R
authors.lastname: Almeyda
authors.forename: J
authors.initials: J
authors.lastname: Capper
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery*; D000287:Administration, Topical; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004391:Dust; D004724:Endoscopy; D005005:Ethmoid Sinus / Q000187:drug effects / Q000601:surgery*; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D009784:Occupational Diseases / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery*; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery*; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D016879:Salvage Therapy; D014934:Wood
chemical_list: D000964:Antimetabolites, Antineoplastic; D004391:Dust; D005472:Fluorouracil